Showing results (91-100 of 759) with videos related to
Sort By:
Pageof 76
Nephron|April 22, 2015
A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort studyErica Daina, Paolo Cravedi, Mirella Alpa, et al.Journal of Transplantation|June 12, 2012
Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in TransplantationAlessia Gennarini, Paolo Cravedi, Maddalena Marasà, et al.Diabetes|April 29, 2006
Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretionAneliya I Parvanova, Roberto Trevisan, Ilian P Iliev, et al.Nephron|February 13, 2020
Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement ActivationCamillo Carrara, Manuel Alfredo Podestà, Mauro Abbate, et al.Clinical Journal of the American Society of Nephrology : CJASN|August 8, 2008
Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathyPiero Ruggenenti, Paolo Cravedi, Maria Chiara Sghirlanzoni, et al.Frontiers in Pharmacology|March 17, 2022
Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19Valentina Fanny Leone, Amantia Imeraj, Sara Gastoldi, et al.Diabetes|September 2, 2009
Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICTSalvatore De Cosmo, Nicola Motterlini, Sabrina Prudente, et al.The Journal of Clinical Endocrinology and Metabolism|September 10, 2004
Insulin resistance and proliferative retinopathy: a cross-sectional, case-control study in 115 patients with type 2 diabetesAneliya Parvanova, Ilian Iliev, Marco Filipponi, et al.Clinical Transplants|April 12, 2007
The Bergamo Kidney Transplant ProgramNorberto Perico, Paolo Cravedi, Piero Ruggenenti, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 30, 2023
Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case SeriesManuel Alfredo Podestà, Matias Trillini, Valentina Portalupi, et al.Pageof 76